The table below shows Edgewise Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$42.54M
-$37.87M
-$28.60M
-$22.83M
-$12.57M
-$6.06M
Capital expenditure
$260.00K
$44.00K
$297.00K
$4.37M
$369.00K
$62.00K
Investing cash flow
$2.43M
$43.90M
-$268.31M
$49.04M
$31.39M
-$64.77M
Dividends paid
-
-
-
-
EWTX operating cash flow (10-K history)
Edgewise Therapeutics, Inc. reported operating cash flow of -$143.82M for fiscal year 2025. That is down 31.9% from -$109.03M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$14.63M (FY 2020) to -$143.82M. Figures come from the company's audited annual reports as filed with the SEC.